Although CAP guidelines published in 2010 modified the definition of hormone receptor positivity to <1% for treatment purposes [30], other studies have also shown greater reduction in residual tumor burden after HER2-targeted therapy when <10% vs. <1% was used to define hormone receptor negativity and have led to the formation of the low-positive ER group [31]. Here, ERBB2 is linked to neoplasm.